Date:_August 28, 2021	
Your Name: <u>Toru Arai</u>	
Manuscript Title: Platelet-derived gr	owth factor can predict survival and acute exacerbation in patients with
idiopathic pulmonary fibrosis_	
Manuscript number (if known):	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present	None	
	manuscript (e.g., funding, provision of study materials,	JSPS KAKENHI Grant Number JP17K09636	Payments were made to me.
	medical writing, article		Dayma anta yuana maada ta maa
	processing charges, etc.)	National Hospital	Payments were made to me.
	No time limit for this item.	Organization Grant {H28- NHO (Kokyu)-2}	
	No time innit for this item.	· , , , .	
		Editage, English Editing	Payments for the editing were done by me.
		Time frame: past	36 months
2	Grants or contracts from	_X_None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	_X_None	

4	Consulting fees	_X_None	
5	Payment or honoraria for	None Boehringer Ingelheim	Doumonts ware made to me
	lectures, presentations, speakers bureaus, manuscript writing or educational events	Shionogi Co. Ltd	Payments were made to me. Payments were made to me.
		Smoriogi co. Etu	rayments were made to me.
6	Payment for expert	X None	
	testimony		
7	Support for attending meetings and/or travel	_X_None	
8	Patents planned, issued or	_X_None	
	pending		
9	Participation on a Data	X None	
	Safety Monitoring Board or	_X_None	
	Advisory Board		
10	Leadership or fiduciary role	_X_None	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	X None	
12	Receipt of equipment,	_X_None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	X None	
	financial interests		

TA has received lecture fees from Boehringer Ingelheim and Shionogi for activities not connected with the submitted work.

Please place an "X" next to the following statement to indicate your agreement:		
X I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Date: <u>Dec 28, 2021</u>						
Your Name: Masal	ki Hirose					
Manuscript Title:	Platelet-derived g	growth factor ca	n predict surv	vival and acute	e exacerbation i	n patients with
idiopathic pulmon	ary fibrosis_					
Manuscript numbe	r (if known):					

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	X None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	JSPS KAKENHI grant (number JP17K09636)	
3	Royalties or licenses	<u>X</u> None	

4	Consulting fees	XNone
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	X_None
6	Payment for expert testimony	X None
7	Support for attending meetings and/or travel	X_None
8	Patents planned, issued or pending	X_None
9	Participation on a Data Safety Monitoring Board or Advisory Board	X_None
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	X_None
11	Stock or stock options	X_None
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	X_None
13	Other financial or non- financial interests	X_None

I report a grant from Japanese Society for the Promotion of Science (JSPS), but have no competing interest.		

Please place an "X" next to the following statement to indicate your agreement:
X I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date:	29 th August, 2021
Your N	ame:_Tomoko Kagawa
Manus	cript Title:_ Platelet-derived growth factor can predict survival and acute exacerbation in patients with
idiopat	hic pulmonary fibrosis_
Manus	cript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present	_XNone	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.) No time limit for this item.		
	No time innit for this item.		
		Time frame, nect	26 months
2		Time frame: past	36 months
2	Grants or contracts from	_XNone	
	any entity (if not indicated in item #1 above).		
3	,	V None	
Э	Royalties or licenses	X_None	
4	Consulting fees	X None	
4	Consulting lees	_ <u>^_</u> None	

	Payment or honoraria for	X_None	
	lectures, presentations, speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	X_None	
	testimony		
7	Support for attending meetings and/or travel	_XNone	
8	Patents planned, issued or	X_None	
	pending		
9	Participation on a Data	X_None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	X_None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	_XNone	
12	Receipt of equipment,	<u>X</u> None	
	materials, drugs, medical		
	writing, gifts or other		
12	services	V None	
13	Other financial or non-	_XNone	
	financial interests		

I have no conflict of interests.	

Please place an "X" next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date: 2021/8/31	
Your Name: Kazuyoshi Hatsuda	
Manuscript Title: Platelet-derived growth factor can predict survival and acute exacerbation in patients with	
idiopathic pulmonary fibrosis_	
Manuscript number (if known):	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5	lectures, presentations,	XNone	
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert testimony	XNone	
	testimony		
7	Cumpart for attanding	V N	
/	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	XNone	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	XNone	
	financial interests		
Plea	Please summarize the above conflict of interest in the following box:		

I have no conflict of interests.		

Please place an "X" next to the following statement to indicate your agreement:

X __ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date:_August 28, 2021	
our Name:_Yoshikazu Inoue	
Manuscript Title:_ Platelet-derived growth factor can predict survival and acute exacerbation in patient	s with
diopathic pulmonary fibrosis_	
Manuscript number (if known):	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
		I	planning of the work
1	All support for the present	<u>X</u> None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5	Payment or honoraria for	None	
	lectures, presentations, speakers bureaus, manuscript writing or educational events	Lecture fee	Boehringer Ingelheim (not related to this study)
		Lecture fee	Kyorin (not related to this study)
		Lecture fee	GSK (not related to this study)
		Lecture fee	Shionogi (not related to this study)
6	Payment for expert	<u>X</u> None	
	testimony		
7	Support for attending	<u>X</u> None	
	meetings and/or travel		
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or	Steering committee	Boehringer Ingelheim (Other clinical trial not related to
	Advisory Board		this study)
		Advisory board	Taiho (Other clinical trial not related to this study)
		Steering committee	Roche(Other clinical trial not related to this study)
		Steering committee	GALAPAGOS(Other clinical trial not related to this study)
		Medical advisor	Savara(Other clinical trial not related to this study)
10	Leadership or fiduciary role	X_None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
	-		
12	Receipt of equipment,	None	
	materials, drugs, medical writing, gifts or other	Medical writing	Boehringer Ingelheim (Other manuscripts related to
			other clinical trial not related to this study)
	services		
13	Other financial or non-	XNone	
	financial interests		

YI is members of steering committees or advisor of Boehringer Ingelheim, Taiho, Roche, GALAPAGOS and SAVARA (not related to this study). YI has received lecture fees from Boehringer Ingelheim, Kyorin GSK and Shionogi (not related to this study). YI has received supports of medical writing from Boehringer Ingelheim about other manuscripts related to other clinical trial not related to this study).

Please place an "X" next to the following statement to indicate your agreement:

_X__ I certify that I have answered every question and have not altered the wording of any of the questions on this form.